Skip to main content
. 2021 Jul 20;12(15):1470–1489. doi: 10.18632/oncotarget.28011

Figure 8.

Figure 8

SFN, AZ, and AZ+SFN increase the Nrf2-mediated antioxidant pro-survival pathway in typical H727 (A, B) and atypical H720 (C, D) tumors growing in a NOD/SCID mice using immunohistochemistry assay. Individual necropsy tumors were taken from untreated control (CTRL) and AZ (20 mg/kg), SFN (40 mg/kg), and a combination of AZ (20 mg/kg) plus SFN (40 mg/kg) cohorts treated daily for two weeks, as previously reported [3]. The data represent one out of three independent experiments showing similar results. (E) RT-PCR data show that Keap1 methylation levels did not change significantly following AZ, SFN, and AZ+SFN treatment in BC H720 cells compared to the untreated control. Nrf2 positive cells’ expression was compared to the untreated control for each treatment group by ANOVA using the unpaired t-test with 95% confidence with indicated asterisks for statistical significance. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, n = 3. (F) Schematic regulation of the promoter and methylation of Keap1; The images were created with https://biorender.com/. Abbreviations: AZ: acetazolamide; SFN: sulforaphane; BC: bronchial carcinoma; Nrf2: nuclear factor erythroid 2–related factor 2.